Moderna MRNA Stock
Moderna Price Chart
Moderna MRNA Financial and Trading Overview
| Moderna stock price | 128.32 USD |
| Previous Close | 126.05 USD |
| Open | 126 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 125.08 - 130.19 USD |
| 52 Week Range | 115.03 - 217.25 USD |
| Volume | 3.02M USD |
| Avg. Volume | 3.31M USD |
| Market Cap | 49.55B USD |
| Beta (5Y Monthly) | 1.697464 |
| PE Ratio (TTM) | 10.904362 |
| EPS (TTM) | -12.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 215.93 USD |
MRNA Valuation Measures
| Enterprise Value | 41.73B USD |
| Trailing P/E | 10.904362 |
| Forward P/E | -29.743708 |
| PEG Ratio (5 yr expected) | 1.29 |
| Price/Sales (ttm) | 3.2903607 |
| Price/Book (mrq) | 2.6460648 |
| Enterprise Value/Revenue | 2.771 |
| Enterprise Value/EBITDA | 8.066 |
Trading Information
Moderna Stock Price History
| Beta (5Y Monthly) | 1.697464 |
| 52-Week Change | 1.52% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 217.25 USD |
| 52 Week Low | 115.03 USD |
| 50-Day Moving Average | 134.68 USD |
| 200-Day Moving Average | 152.95 USD |
MRNA Share Statistics
| Avg. Volume (3 month) | 3.31M USD |
| Avg. Daily Volume (10-Days) | 2.82M USD |
| Shares Outstanding | 381.21M |
| Float | 344.06M |
| Short Ratio | 5.44 |
| % Held by Insiders | 9.60% |
| % Held by Institutions | 68.32% |
| Shares Short | 18.72M |
| Short % of Float | 6.52% |
| Short % of Shares Outstanding | 4.90% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 31.76% |
| Operating Margin (ttm) | 32.05% |
| Gross Margin | 39.81% |
| EBITDA Margin | 34.35% |
Management Effectiveness
| Return on Assets (ttm) | 11.66% |
| Return on Equity (ttm) | 26.62% |
Income Statement
| Revenue (ttm) | 15.06B USD |
| Revenue Per Share (ttm) | 38.61 USD |
| Quarterly Revenue Growth (yoy) | -69.29% |
| Gross Profit (ttm) | 10.55B USD |
| EBITDA | 5.17B USD |
| Net Income Avi to Common (ttm) | 4.78B USD |
| Diluted EPS (ttm) | 11.92 |
| Quarterly Earnings Growth (yoy) | -97.79% |
Balance Sheet
| Total Cash (mrq) | 8.92B USD |
| Total Cash Per Share (mrq) | 23.41 USD |
| Total Debt (mrq) | 1.11B USD |
| Total Debt/Equity (mrq) | 5.87 USD |
| Current Ratio (mrq) | 3.464 |
| Book Value Per Share (mrq) | 49.122 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 993M USD |
| Levered Free Cash Flow (ttm) | 541.88M USD |
Profile of Moderna
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 200 Technology Square |
| ZIP | 02139 |
| Phone | 617 714 6500 |
| Website | https://www.modernatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3900 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Moderna Stock
What is a current MRNA stock price?
Moderna MRNA stock price today per share is 128.32 USD.
How to purchase Moderna stock?
You can buy MRNA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Moderna?
The stock symbol or ticker of Moderna is MRNA.
Which industry does the Moderna company belong to?
The Moderna industry is Biotechnology.
How many shares does Moderna have in circulation?
The max supply of Moderna shares is 313.72M.
What is Moderna Price to Earnings Ratio (PE Ratio)?
Moderna PE Ratio is now.
What was Moderna earnings per share over the trailing 12 months (TTM)?
Moderna EPS is -12.33 USD over the trailing 12 months.
Which sector does the Moderna company belong to?
The Moderna sector is Healthcare.
Moderna MRNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| S&P 500 INDEX SPX | 5123.41 USD — |
-1.46
|
2.41B USD — | 5107.94 USD — | 5175.03 USD — | — - | 2.41B USD — |
| S&P 500 (Yahoo.com) GSPC | 5123.41 USD — |
-1.46
|
2.41B USD — | 5107.94 USD — | 5175.03 USD — | — - | 2.41B USD — |
| US100 NDX | 18003.49 USD — |
-1.66
|
866.13M USD — | 17952.09 USD — | 18166.49 USD — | — - | 866.13M USD — |
| Nasdaq US CapEx Achievers Index CAPEXA | 2748.81 USD — |
-1.45
|
— — | 2740.46 USD — | 2771.68 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| Nasdaq-100 ESG Net Notional Tot NDXESG24 | 1502.41 EUR 1642.34 USD |
-0.99
|
— — | 1496.77 EUR 1636.17 USD | 1514.56 EUR 1655.62 USD | — - | — — |
| NASDAQ 100 Equal Weighted NDXE | 7278.7 USD — |
-1.88
|
— — | 7263.41 USD — | 7351.66 USD — | — - | — — |
| Nasdaq-100 Notional Net Return XNDXNNREUR | 3502.97 EUR 3829.22 USD |
-0.97
|
— — | 3489.87 EUR 3814.9 USD | 3531.5 EUR 3860.4 USD | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| Nasdaq-100 Micro Index XND | 180.03 USD — |
-1.66
|
— — | 179.52 USD — | 181.66 USD — | — - | — — |
| NASDAQ 100 Pre Market Indicator QMI | 18108.85 USD — |
-1.09
|
— — | 18108.6 USD — | 18246.69 USD — | — - | — — |
| NASDAQ-100 Reduced Value Index NQX | 3600.7 USD — |
-1.66
|
— — | 3590.42 USD — | 3633.3 USD — | — - | — — |
| NASDAQ Global Buyback Achievers DRBG | 2057.38 USD — |
-0.89
|
— — | 2057.25 USD — | 2057.65 USD — | — - | — — |
- {{ link.label }} {{link}}